Module

Current Standards in Recurrent Ovarian Cancer

Source: Managing Ovarian Cancer Recurrence: Coupling Novel Therapeutics With Optimal Treatment Decisions

Current Standards in Recurrent Ovarian Cancer

Faculty:

J. Tate Thigpen, MD

CME CREDIT INFORMATION

Release Date: 08/15/08

Expiration Date: 08/14/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.9 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss options for the treatment of patients with newly diagnosed ovarian cancer
Describe the importance of the extent of disease at the time of initial diagnosis in determining therapy for ovarian cancer
Articulate the differences in treatment options between chemosensitive and chemoresistant patients with recurrent ovarian cancer
Cite recent data on targeted agents in the treatment of patients with recurrent or progressive ovarian cancer

Topics covered include:

Clinically Relevant Features of Ovarian Cancer
Clinical Management of Newly Diagnosed Ovarian Cancer
Management Considerations Following Initial Therapy
Systemic Therapy for Patients With Chemosensitive Ovarian Cancer
Systemic Therapy for Patients With Chemoresistant Ovarian Cancer

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.